Paul Hastings LLP, a leading global law firm, announced today that it advised Dong-A Pharmaceutical Co., Ltd. (Dong-A), a leading Korean pharmaceutical company, on its long-term strategic collaboration partnership with Meiji Seika Pharma Co., Ltd (Meiji), a Japanese pharmaceutical company, with respect to biosimilars.
As part of the strategic collaboration partnership, Dong-A and Meiji will establish a joint venture company and construct a cGMP-compliant biosimilar construction plant in Songdo, South Korea to target the global markets with antibody based drugs, including Herceptin. Dong-A and Meiji will also collaborate on the research, development, manufacture and commercialization of biosimilar products in global markets. The strategic collaboration partnership between Dong-A and Meiji is expected to enable the parties to share their respective biopharmaceutical technologies and globally expand their respective biosimilars businesses.
Corporate partners Matthew Berger and Daniel Kim and associates Tiffany Lee and Dongho Lee led the Paul Hastings team.
Related Posts:
- None Found